<DOC>
	<DOCNO>NCT01809860</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose isavuconazole pharmacokinetics ( PK ) sirolimus single dose administration .</brief_summary>
	<brief_title>A Study Evaluate Effect Multiple Doses Isavuconazole Pharmacokinetics Single Dose Sirolimus Healthy Subjects</brief_title>
	<detailed_description>Subjects receive single dose sirolimus Day 1 follow 21 day wash-out period ( time sirolimus dose isavuconazole dosing ) . On Days 22 23 , isavuconazole dose three time daily ( TID ) . On Days 24 34 , isavuconazole administer daily ( QD ) . All subject administer single dose sirolimus Day 26 .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>The subject body weight least 45 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive Results aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) must within normal range The female subject agree sexual abstinence , surgically sterile , postmenopausal ( define least 2 year without menses ) , use medically acceptable double barrier method ( e.g . spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method Screening 3 week followup visit end study ; lactate pregnant document negative pregnancy test The male subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy agree continue use method Screening 3 week followup visit end study The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) The subject history tuberculosis exposure anyone know suspected tuberculosis illness , opinion investigator , might confound result study pose additional risk administer study drug subject The subject positive result hepatitis C antibody , hepatitis B surface antigen , QuantiFERONÂ®TB Gold test know positive human immunodeficiency virus ( HIV ) . The subject know suspect allergy component trial product include prednisone azole class compound , history multiple and/or severe allergy drug food , history severe anaphylactic reaction The subject smoker ( use tobacco nicotine containing product ) within 6 month prior Screening The subject treatment prescription drug complementary alternative medicine within 14 day prior Day 1 , overthecounter medication within 1 week prior Day 1 , exception acetaminophen 2 g/day The subject recent history ( within last 2 year ) drug alcohol abuse , positive drug and/or alcohol screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>isavuconazole</keyword>
	<keyword>sirolimus</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>